Literature DB >> 29735445

[Effect of intrahippocampal injection of anti-cellular prion protein monoclonal antibody on cognitive deficits in APPswe/PSEN1dE9 transgenic mice].

Hai-Ying Zhang1, Yi-Heng Liu, Yuan Fu, Peng-Cheng Chen, Rui Lu, Jian-Xing Li, Ming-Hui Chen, Hao-Chi Yang, Yu-Sheng Zhang.   

Abstract

OBJECTIVE: To study the effects of intrahippocampal injection of cellular prion protein (PrPC) antibody on cognitive deficits of APPswe/PSEN1dE9 transgenic mice.
METHODS: Eight-month-old male APPswe/PSEN1dE9 transgenic mice were subjected to bilateral intrahippocampal injection of a single dose (2 µL) of anti-PrPC monoclonal antibody (EP1802Y) or PBS, with wild-type C57Bl/6J mice serving as the control group. After two months, the mice were tested for cognitive behaviors using open filed (OF) test, Morris water maze (MWM) test, fear conditioning (FC) test, and novel object recognition (NOR) test, and immunohistochemistry was used to examine the changes in hippocampal expression of Aβ1-42.
RESULTS: The EP1802Y-treated and PBS-treated mice showed no significantly differences in the performance in OF test in terms of central activity time or total distance of activity (P>0.05), nor in NOR test in terms of novel object recognition index (P>0.05). In MWM test, the EP1802Y-treated and PBS-treated mice showed significantly reduced crossings of the hidden platform as compared with the wild-type mice (P<0.05), but EP1802Y-treated mice had a significantly shorter swimming distance to find the platform than PBS-treated mice (P<0.05). No significant differences were found in the results of FC test among the 3 groups. Immunohistochemistry revealed a significantly reduced expression of Aβ1-42 in the hippocampus of EP1802Y-treated mice.
CONCLUSION: Intrahippocampal injection of PrPC antibody can improve cognitive deficits of APPswe/PSEN1dE9 transgenic mice, which sheds light on a novel therapeutic approach for Alzheimer's disease that targets PrPC to lower the toxicity of Aβ oligomer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29735445      PMCID: PMC6765653     

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  22 in total

1.  Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.

Authors:  Clemens Falker; Alexander Hartmann; Inga Guett; Frank Dohler; Hermann Altmeppen; Christian Betzel; Robin Schubert; Dana Thurm; Florian Wegwitz; Pooja Joshi; Claudia Verderio; Susanne Krasemann; Markus Glatzel
Journal:  J Neurochem       Date:  2016-03-02       Impact factor: 5.372

2.  Neuroscience: Alzheimer's disease.

Authors:  Lennart Mucke
Journal:  Nature       Date:  2009-10-15       Impact factor: 49.962

3.  Relationship between Cognitive Performance and Measures of Neurodegeneration among Hispanic and White Non-Hispanic Individuals with Normal Cognition, Mild Cognitive Impairment, and Dementia.

Authors:  Shanna L Burke; Miriam J Rodriguez; Warren Barker; Maria T Greig-Custo; Monica Rosselli; David A Loewenstein; Ranjan Duara
Journal:  J Int Neuropsychol Soc       Date:  2017-09-18       Impact factor: 2.892

4.  Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.

Authors:  Takahiro Aimi; Koichiro Suzuki; Tatsuya Hoshino; Tohru Mizushima
Journal:  J Neurochem       Date:  2015-06-10       Impact factor: 5.372

5.  Ropren® treatment reverses anxiety-like behavior and monoamines levels in gonadectomized rat model of Alzheimer's disease.

Authors:  Julia Fedotova; Vagif Soultanov; Tamara Nikitina; Victor Roschin; Natalia Ordyan; Lucian Hritcu
Journal:  Biomed Pharmacother       Date:  2016-09-06       Impact factor: 6.529

6.  Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models.

Authors:  Mikhail A Kostylev; Adam C Kaufman; Haakon B Nygaard; Pujan Patel; Laura T Haas; Erik C Gunther; Alexander Vortmeyer; Stephen M Strittmatter
Journal:  J Biol Chem       Date:  2015-05-27       Impact factor: 5.157

7.  Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites.

Authors:  Darragh B Freir; Andrew J Nicoll; Igor Klyubin; Silvia Panico; Jessica M Mc Donald; Emmanuel Risse; Emmanuel A Asante; Mark A Farrow; Richard B Sessions; Helen R Saibil; Anthony R Clarke; Michael J Rowan; Dominic M Walsh; John Collinge
Journal:  Nat Commun       Date:  2011-06-07       Impact factor: 14.919

8.  Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies.

Authors:  Fulvio Florenzano; Corsetti Veronica; Gabriele Ciasca; Maria Teresa Ciotti; Anna Pittaluga; Gunedalina Olivero; Marco Feligioni; Filomena Iannuzzi; Valentina Latina; Michele Francesco Maria Sciacca; Alessandro Sinopoli; Danilo Milardi; Giuseppe Pappalardo; De Spirito Marco; Massimiliano Papi; Anna Atlante; Antonella Bobba; Antonella Borreca; Pietro Calissano; Giuseppina Amadoro
Journal:  Oncotarget       Date:  2017-04-22

Review 9.  Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease.

Authors:  Sangyun Jeong
Journal:  Mol Cells       Date:  2017-09-20       Impact factor: 5.034

10.  Computational investigation of Amyloid-β-induced location- and subunit-specific disturbances of NMDAR at hippocampal dendritic spine in Alzheimer's disease.

Authors:  Jingyi Liang; Don Kulasiri; Sandhya Samarasinghe
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.